[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@pfizer_news Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::540233480.png) @pfizer_news Pfizer Inc.

Pfizer Inc. posts on X about sunday, cest, new england, acquisition the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::540233480/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::540233480/c:line/m:interactions.svg)

- X Week XXXXX +266%
- X Month XXXXX -XX%
- X Months XXXXXX +29,775%
- X Year XXXXXX +168%

### Mentions: XX [#](/creator/twitter::540233480/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::540233480/c:line/m:posts_active.svg)

- X Month XX +27%
- X Months XX +700%
- X Year XX +20%

### Followers: XXXXXX [#](/creator/twitter::540233480/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::540233480/c:line/m:followers.svg)

- X Week XXXXXX -XXXX%
- X Month XXXXXX -XXXX%
- X Months XXXXXX +0.38%
- X Year XXXXXX -XXXX%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::540233480/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::540233480/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  XX% [finance](/list/finance)  XXXX%

**Social topic influence**
[sunday](/topic/sunday) 6.25%, [cest](/topic/cest) 6.25%, [new england](/topic/new-england) 6.25%, [acquisition](/topic/acquisition) 6.25%, [investment](/topic/investment) 6.25%, [future](/topic/future) XXXX%

**Top accounts mentioned or mentioned by**
[@usfda](/creator/undefined) [@biontechgroup](/creator/undefined) [@potus](/creator/undefined) [@astellasus](/creator/undefined) [@merck](/creator/undefined) [@metserainc](/creator/undefined) [@bloodportfolio](/creator/undefined) [@watterscat4](/creator/undefined) [@xfreespeech3](/creator/undefined) [@usa_eu_s_hunter](/creator/undefined) [@mbqasim01](/creator/undefined) [@suzannereads](/creator/undefined) [@meantweetsrule](/creator/undefined)
### Top Social Posts
Top posts by engagements in the last XX hours

"Today we announced that the FDA has approved a new perioperative regimen for certain people with cisplatin-ineligible muscle-invasive bladder cancer providing hope to this community that has faced limited treatment options for decades. Learn more:"  
[X Link](https://x.com/pfizer_news/status/1991936977571127685)  2025-11-21T18:29Z 33.8K followers, XXX engagements


"At #ESMO25 were presenting updated overall survival data from our Phase X study of a targeted combination therapy in patients with metastatic non-small cell #LungCancer (NSCLC) with a BRAF V600E mutation. Stay tuned for the presentation on Sunday 10/19 at 8:30 am CEST"  
[X Link](https://x.com/pfizer_news/status/1979155432665919854)  2025-10-17T12:00Z 33.8K followers, XXX engagements


"At #ESMO25 we're presenting positive event-free survival and overall survival results in cisplatin-ineligible patients with muscle-invasive #BladderCancer from a Phase X trial with @AstellasUS and @Merck. Learn more:"  
[X Link](https://x.com/pfizer_news/status/1979557020991627511)  2025-10-18T14:35Z 33.8K followers, XXX engagements


"At #ESMO25 were highlighting the momentum of our extensive Oncology portfolio to redefine the cancer care continuum across 45+ abstracts with XX oral/mini oral presentations. Learn more:"  
[X Link](https://x.com/pfizer_news/status/1971166180212654100)  2025-09-25T10:53Z 33.8K followers, XXX engagements


"Encouraging news for the HER2+ metastatic #BreastCancer community: Our Phase X trial demonstrated improved progression-free survival with a new investigational combination for first-line maintenance. Learn more:"  
[X Link](https://x.com/pfizer_news/status/1978050334103605660)  2025-10-14T10:48Z 33.8K followers, 3969 engagements


"Today at #ESMO25 we presented updated overall survival data from our Phase X study of a targeted combination therapy in patients with metastatic non-small cell #LungCancer (NSCLC) with a BRAF V600E mutation. Learn more:"  
[X Link](https://x.com/pfizer_news/status/1979849848657502450)  2025-10-19T09:59Z 33.8K followers, XXX engagements


"At #ESMO25 were sharing final overall survival data from a Phase X study in men with a form of non-metastatic hormone-sensitive prostate cancer (nmHSPC). Learn more about the research which was also simultaneously published in the New England Journal of Medicine: Among men with this form of nmHSPC the risk of developing metastatic disease is high so early intervention with effective therapy is critical. These data show the potential of our therapy to make a meaningful impact and offer new hope for men facing #ProstateCancer"  
[X Link](https://x.com/pfizer_news/status/1979857585420308644)  2025-10-19T10:30Z 33.8K followers, XXX engagements


"At #ESMO25 new health-related quality-of-life data that complement previously reported efficacy results from a Phase X study for our CDK4/6 inhibitor in HR+ HER2+ advanced #BreastCancer will be presented"  
[X Link](https://x.com/pfizer_news/status/1979880207990272505)  2025-10-19T12:00Z 33.8K followers, XXX engagements


"Today we announced that Pfizer completed the acquisition of @MetseraInc a strategic milestone representing our investment in the future of medicine for obesity and cardiometabolic disease. Learn more:"  
[X Link](https://x.com/pfizer_news/status/1989011506910883840)  2025-11-13T16:44Z 33.8K followers, XXX engagements


"At #ASH25 we're highlighting data from 30+ abstracts across our portfolio and pipeline in blood cancers and rare blood disorders. We're focused on understanding and supporting the unique needs of patients. Learn more:"  
[X Link](https://x.com/pfizer_news/status/1995538381636264046)  2025-12-01T17:00Z 33.8K followers, XXX engagements


"At #ASH25 were excited to share positive results from our Phase X study in people with hemophilia A or B with inhibitors. Learn more about the data presented which were simultaneously published in @BloodPortfolio:"  
[X Link](https://x.com/pfizer_news/status/1997433394406252607)  2025-12-06T22:30Z 33.8K followers, 1292 engagements


"At #SABCS25 were sharing XX abstracts including Phase X data in HER2+ disease insights supporting our late-stage HR+ HER2- pipeline and real-world evidence as we work to advance care and deliver meaningful progress for people with metastatic #BreastCancer"  
[X Link](https://x.com/pfizer_news/status/1998105296942624786)  2025-12-08T19:00Z 33.8K followers, XXX engagements